



# Pfizer Heritage in Biologics

---

# Biosimilars Will Play a Growing Role in Healthcare



**Physicians**



**Payers**



**Patients**



**Nurses**



**Pharmacists**

- Biosimilars provide the potential to offer a broader range of treatment options for patients, providers, and payers
- As potentially more affordable alternatives to originator biologics that have lost exclusivity, biosimilars may improve access and provide cost savings to healthcare systems


# Pfizer Is a Well-Established Pharmaceutical Manufacturer With a Comprehensive Portfolio

- Pfizer brings therapies to patients in over 175 markets in many therapeutic areas<sup>1</sup>
- Therapies include those that are:
  - Small Molecules
    - Branded
    - Off-patent generic
  - Biologics
    - Innovative
    - Biosimilar
- Over 30 years of experience manufacturing biologics at the industry's leading edge<sup>2</sup>
- Nearly 10 years of experience outside the US manufacturing biosimilars<sup>3</sup>
- Investing in biosimilars with a focus on inflammation and oncology<sup>4</sup>



# Pfizer Biosimilars Value Chain

**Pfizer Has the Infrastructure and Experience to Support a Global Biosimilars Business That Leverages Pfizer's Strong Capabilities and Footprint Across Our Value Chain**



# Pfizer's Culture of Quality Forms the Foundation for Excellence in Manufacturing Biosimilars

- Rich history of innovation in manufacturing
- Quality-by-design principles for production
- Commitment to continuous improvement process
- Current Good Manufacturing Practice (CGMP) standards in quality control, supported by advanced technologies and scientific expertise
- State-of-the-art production, informed by proprietary design and execution



# Pfizer's Culture of Quality Helps Patients to Benefit From a Sustainable Supply of Quality Products

- Through consistent high standards for quality, compliance, and supply reliability, Pfizer's global supply network provides
  - Fast, flexible solutions across the full manufacturing and supply chain spectrum
  - Delivery of quality medicines around the world



# Pfizer Brings Innovation for Sustainable Healthcare



## Brings Innovation to Healthcare by

- Developing innovative treatments
- Developing biosimilars to innovative treatments for sustainable healthcare and potentially expanded access

# Pfizer Biosimilars in Market

2007

2016

- Three marketed biosimilars outside the US<sup>1</sup>
- Four mAbs in Phase 3<sup>2</sup>
- Investing in biosimilars with a focus on inflammation and oncology<sup>2</sup>



mAb, monoclonal antibody

1. European Medicines Agency Website. European Public Assessment Reports for Retacrit, Nivestim, and Inflectra.

2. Pfizer Pipeline Update. February 2, 2016.



# Key Points

- Biosimilars have the potential to offer a broader range of treatment options for patients, physicians, and payers
- Leveraging Pfizer's global presence and expertise in research and development, regulatory science, and commercialization will help deliver high-quality and effective biosimilars to patients with difficult-to-treat diseases
- Pfizer Biosimilars will help continue Pfizer's commitment to providing additional options in inflammation and oncology treatments that impact the lives of patients worldwide



Thank You!

---